U.S. NUCLEAR REGULATORY COMMISSION

Amendment No. 56

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	In accordance with letter dated **September 19, 2015,**
1. **SSM Health St. Clare Hospital - Fenton**	3. License No. 24-11858-01 is amended in its entirety to read as follows:
2. 1015 Bowles Avenue Fenton, Missouri 63026	4. Expiration Date: September 30, 2025
	5. Docket No. 030-02368 Reference No.

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As needed
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As needed
C. Any byproduct material permitted by 10 CFR 35.300	C. Any	C. 2 curies
D. Iridium-192 permitted by 10 CFR 35.400	D. Sealed sources (Best Medical International, Inc., Model 81-01)	D. 1 curie
E. Iodine-125 permitted by 10 CFR 35.400	E. Sealed sources (Best Medical International, Inc., Models 2301 to 2316; North American Scientific, Inc., Model Med 3631; Core Oncology, Inc. (formerly Mills Biopharmaceuticals, LLC) Model I-125 SL (Prostaseed); International Brachytherapy SA Model 1251L; Syncor Pharmaceuticals, Inc., Model BT-125-1; Medi-Physics, Inc., Model 6711 (OncoSeed™); IsoAid, L.L.C., Model IAI-125A (Advantage™ I-125); Implant Sciences Corp. Model 3500 (I-plant); and Bard Brachtherapy, Inc., Model STM 1251)	E. 1 curie

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License No.
24-11858-01

Docket or Reference No.
030-02368

Amendment No. 56

F. Palladium-103 permitted by 10 CFR 35.400	F. Sealed sources (Best Medical International, Inc., Models 2331 and 2335; North American Scientific, Inc., Model Med 3633; Theragenics Corporation Theraseed Model 200; Mills Biopharmaceuticals Model 103 SL; International Brachytherapy SA Model 1031L; Medi-Physics, Inc., Model 6733 (EchoSeed™); and IsoAid, L.L.C., Model IAPd-103A (Advantage™ Pd-103)).	F. 1 curie

9. Authorized use:

A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.

B. Any imaging and localization study permitted by 10 CFR 35.200.

C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.

D. through F. Any manual brachytherapy procedure permitted by 10 CFR 35.400.

CONDITIONS

10. Licensed material may be used or stored only at the licensee's facilities located at 1015 Bowles Avenue, Fenton, Missouri.

11. The Radiation Safety Officer (RSO) for this license is Andre Strzembosz, M.D.

12. Licensed material is only authorized for use by, or under the supervision of:

A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.

B. The following individuals are authorized users for medical use as indicated:

Authorized User	Material and Use
David Morris, M.D.	10 CFR 35.300 and 35.400.
Ronald Palmer, M.D.	10 CFR 35.100, 35.200, and 35.300.
Andre Strzembosz, M.D.	10 CFR 35.100, 35.200, and 35.300.
Karen J. Baranski, M.D.	10 CFR 35.100 and 35.200.

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License No.
24-11858-01

Docket or Reference No.
030-02368

Amendment No. 56

Authorized User	Material and Use
Thomas P. Bocchini, M.D.	10 CFR 35.100 and 35.200.
Robert J. Gresick, M.D.	10 CFR 35.100 and 35.200.
Megan Maine Gau, M.D.	10 CFR 35.100 and 35.200.
Robert Swanson, M.D.	10 CFR 35.300 and 35.400 (limited to the use of palladium-103 and iodine-125).
John Bedwinek, M.D.	10 CFR 35.300 and 35.400.
John Joseph Stephens, M.D.	10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide I-131).
Thomas M. Schroyer, M.D.	10 CFR 35.100 and 35.200.
Rebecca J. Mueller, M.D.	10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide I-131).

13. The licensee is authorized to transport licensed material only in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."

14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U. S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

A. Application dated April 20, 2015 (ML15118A911)
B. Letter dated September 29, 2015 (ML15273A058)

FOR THE U. S. NUCLEAR REGULATORY COMMISSION

Date NOV 25 2015

By Toye L. Simmons

Toye L. Simmons
Materials Licensing Branch
Region III